Antibody sales are predicted to reach $50 billion this year. This Insight Pharma Report focuses on recent developments in the therapeutic antibody field and new technologies built on the foundations of previously successful and unsuccessful strategies. Following a review of the business environment and market forces, this report examines:
•The state of the art, and the needs and direction, of antibody technology today
•Antibody conjugates and other payloads: construction, clinical development, and corporate activity
•Multispecific and multifunctional antibodies: construction, clinical development, and corporate activity
•Development of biosimilars and biobetters: commercial and regulatory issues
•Advances in product development technologies and overcoming biomanufacturing challenges
•IP challenges, deal structures, mergers and acquisitions
•Marketed and clinical pipeline products, current status and future forecast
•Strategies, technologies, and pipelines of selected new-generation antibody companies
•Future potential impact of systems biology and nanotechnology
•Strategic issues, economic outlook, and opportunities for future products
•Insights from thought leaders interviewed for this report
The commercial clinical pipeline for antibodies is growing at a rate of 50–55 new mAbs per year. Today, about 314 mAb products are in clinical trials worldwide. The New Generation of Antibody Therapeutics:
A number of immunotoxins currently in clinical trials are antibody-based reagents. As discussed in this Insight Pharma Report, a number of targets, drugs, and linkers are being evaluated. The last few years have seen striking improvements in the development of antibody-drug conjugate technology; it is clear that in the next few years a wave of such products will gain approval. Firms that profess expertise in the synthesis of immunoconjugates are discussed in this report.
Bispecific antibodies present unique possibilities for disease treatment. There is substantial interest in bispecific antibodies as a means to overcome some of the shortcomings of conventional recombinant antibodies that have slowed their successful performance and prevented FDA approval. Today, numerous bispecific antibodies are in clinical trials and may provide a new generation of antibody technologies. This Insight Pharma Report profiles selected bispecific antibody companies and cutting-edge concepts in bispecific antibody development.
The New Generation of Antibody Therapeutics:
Predictions for the future of cutting-edge antibody technologies are that robust growth will continue despite the many roadblocks and uncertainties in the overall picture of drug development. While the market will continue to be dominated by whole antibody molecules, it is anticipated that bispecific antibodies and antibody-drug conjugates will be a growing component of the overall market.
For more information and to purchase this Insight Pharma Report, visit: http://www.InsightPharmaReports.com
About Insight Pharma Reports
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute. http://www.InsightPharmaReports.com